Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

NCT04903626 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

286

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus (HCV)

Interventions

DRUG: Glecaprevir/Pibrentasvir (GLE/PIB)

Sponsor

AbbVie